Sign in

CIK 0001907108

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Lexeo Therapeutics, Inc.

Sign in to watch
Ticker
LXEO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
854012572
Phone
+1 212-547-9879
Business address
345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
  1. 4 Open-market sale Chief Medical Officer sold 585 shares at $2.77 ($1,623)
  2. 4 Open-market sale Chief Legal Officer sold 521 shares at $2.77 ($1,445)
  3. 4 Open-market sale Chief Development Officer sold 367 shares at $2.77 ($1,018)
  4. 4 Grant or award Chief Technical Officer acquired 5,720 shares (grant or award)
  5. 4 Grant or award Chief Legal Officer acquired 5,720 shares (grant or award)
  6. 4 Grant or award Chief Development Officer acquired 5,720 shares (grant or award)
  7. 4 Grant or award Chief Executive Officer acquired 2,128 shares (grant or award)
  8. 4 Open-market sale Chief Executive Officer sold 4,326 shares at $4.41 ($19,091)
  9. 4 Open-market sale Chief Development Officer sold 1,486 shares at $4.41 ($6,558)
  10. 4 Open-market sale Chief Medical Officer sold 2,359 shares at $4.41 ($10,410)
  11. 4 Open-market sale Chief Legal Officer sold 2,101 shares at $4.41 ($9,272)
  12. 4 Grant or award Chief Financial Officer acquired 40,875 shares (grant or award)
  13. 4 Grant or award Chief Executive Officer acquired 103,750 shares (grant or award)
  14. 4 Grant or award Chief Technical Officer acquired 26,250 shares (grant or award)
  15. 4 Grant or award Chief Legal & Admin Officer acquired 36,250 shares (grant or award)
  16. 4 Grant or award Chief Development Officer acquired 38,750 shares (grant or award)
  17. 4 Grant or award Chief Medical Officer acquired 43,750 shares (grant or award)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Planned sale Chief Executive Officer sold 2,500 shares at $8.20 ($20,491)
  20. 4 Open-market buy Director bought 15,000 shares at $6.99 ($104,852)

Page 4 of 7 · 121 filings